(Update: The NIH provided a response to our comments on July 16, 2018) Below are comments sent by KEI, UACT and HealthGap, regarding a proposed exclusive license to Morphiex Biotherapeutics, an entity for which little is known. The license concerns… Continue Reading
The revised Chair’s text (SCCR/36/6) is very responsive to the broadcasters, and mostly hostile to the civil society groups’ positions, on issues such as term and exceptions, and extending the right to materials delivered over the Internet. One bright spot… Continue Reading
I’m about to deliver this intervention at the WIPO SCCR 36 meeting, as a general statement on limitations and exceptions. We are given 2 minutes. KEI has three points 1. The 1971 Berne Annex, which deals with access for developing… Continue Reading
On May 28, 2018, at the opening of a five day to talks at the 36th WIPO Standing Committee on Copyright and Related Rights (SCCR), 11 civil society and library groups sent a letter to negotiators expressing deep concerns over… Continue Reading
The below are comments were filed by KEI and HealthGap on May 22, 2018, regarding a proposed NIH exclusive license on patents for the treatment and diagnosis of Crohn’s Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis to Precision IBD… Continue Reading
On Wed, May 16, 2018, the House Ways & Means Committee held a markup on HR. 5773, a bill dealing with the opioid crisis, which would require Medicare prescription drug plans to establish drug management programs for at-risk beneficiaries. Representative… Continue Reading
These are provisions on the right to be forgotten in the European Union’s General Data Protection Regulation (GDPR). (KEI does not support the right to be forgotten). http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32016R0679&from=EN REGULATION (EU) 2016/679 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
KEI was invited to participate in the “WHO Global Dialogue on Partnerships for Sustainable Financing of Noncommunicable Disease (NCD) Prevention and Control,” which was held in Copenhagen, Denmark, April 9-11, 2018. A web page for the event is here. Overall,… Continue Reading
On March 21, 2018, KEI asked the NIH to investigate the failure of James Griffin, the Dana-Farber Cancer Institute and Novartis to disclose millions of dollars in NIH grants related to two patents for the leukemia drug midostaurin, marketed by… Continue Reading